Endocannabinoid System 內(nèi)源性大麻素系統(tǒng)課件_第1頁
Endocannabinoid System 內(nèi)源性大麻素系統(tǒng)課件_第2頁
Endocannabinoid System 內(nèi)源性大麻素系統(tǒng)課件_第3頁
Endocannabinoid System 內(nèi)源性大麻素系統(tǒng)課件_第4頁
Endocannabinoid System 內(nèi)源性大麻素系統(tǒng)課件_第5頁
已閱讀5頁，還剩51頁未讀， 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請進(jìn)行舉報或認(rèn)領(lǐng)

文檔簡介

Targetingtheendocannabinoidsystem:

toenhanceorreduce?VincenzoDMNATUREREVIEWS|DRUGDISCOVERY,2008Targetingtheendocannabinoid1IntroductionUpsanddownsofendocannabinoidsindiseaseTherapeuticuseofindirectagonistsTherapeuticuseofinverseagonists/antagonistsIntroduction2CannabinoidEndocannabinoidAnandamide2-AGCannabinoid3EndocannabinoidSystem內(nèi)源性大麻素系統(tǒng)課件4RecptorsCannabinoidreceptorsCB1andCB2Anandamidehashighestaffinity2-AGhashighestefficacyRetrogradesignallingOther“receptors”ofcannabinoidTRPV1GPR55???PPARs-alpha/beta???RecptorsCannabinoidreceptors5EndocannabinoidSystem內(nèi)源性大麻素系統(tǒng)課件6DevelopmentstrategyofendocannabinoidsystemtargeteddrugDirectagonist×TetrahydrocannabinolanditssyntheticanaloguesNewerdrugs√InhibiterofendocannabinoiddegradationSA-47URB597Cannabinoidreceptor(CB)antagonistsRimonabantTaranabantDevelopmentstrategyofendoca7IntroductionUpsanddownsofendocannabinoidsindiseaseTherapeuticuseofindirectagonistsTherapeuticuseofinverseagonists/antagonistsIntroduction8NOTEMeasurementAmountsofendocannabinoid×Changesofendocannabinoidlevel√BidirectionalorparadoxeffectsPositiveandnegativeProtectiveandworseningMultiplefunctionaloutcomeNOTEMeasurement9EattingdisordersPhysiologicalconditionAdaptiveresponseIntakeoffoodCopewiththelackoffoodPathologicalconditionDisruptedorexigenicmechanismEattingdisordersPhysiological10Neural-diseaseNeurodegenerationParlinson’sdiseaseBeta-amyloid-cytotoxicity(AD)MultiplesclerosisandexperimentalallergicencephalitisAmyotrophiclateralsclerosisAnxietyanddepressionPainandinflammationNeural-diseaseNeurodegeneratio11EndocannabinoidSystem內(nèi)源性大麻素系統(tǒng)課件12Rolesofendocannabinoidsduring

centralneuroinflammationRolesofendocannabinoidsduri13Rolesofendocannabinoidsduring

peripheralneuroinflammationRolesofendocannabinoidsduri14LiverdiseaseandosteoporosisDetrimentalandbeneficialeffectsofCB1andCB2respectivelyHepaticpathologyChronicupregulationofendocannabinoidlevelOsteoporosisLiverdiseaseandosteoporosis15OtherdiseasesCancerGastrointestinalinflammationOtherdiseases16IntroductionUpsanddownsofendocannabinoidsindiseaseTherapeuticuseofindirectagonistsTherapeuticuseofinverseagonists/antagonistsIntroduction17InhibitorsofcatabolismInhibitorsofcatabolismFAAHblockers–moreselectivetowardsanandamideMAGLsblockers–specificfor2-AGURB-597(preclinicalstage)AA-5-HT(alsoantagonizeTRPV1)SA-72InhibitorsofcatabolismInhibi18Endocannabinoidindirectagonists:inhibitorsofFAAHandMAGLEndocannabinoidindirectagoni19InhibitorsofcellularreuptakeInhibitorsAromaticacylamidederivativesAM404VDM-11OMDM-1andOMDM-2etc.Carbamoyl-tetrazolesLY2183240(alsoaFAAHinhibitor)PotentialindicationstestedinanimalmodelsInhibitorsofcellularreuptak20Endocannabinoidindirectagonists:InhibitorsofcellularreuptakeEndocannabinoidindirectagoni21Potentialdisadvantages“Off-targets”problem(FAAHinhibitors)Raisenon-endocannabinoidsubstratesActivatenon-cannabinoidreceptors(e.g.TRPV1)AA-5-HT:FAAH/TRPV1blocker(strategy)Somereuptakeinhibitor(AM404)“Nodevelop”(MAGLsinhibitors)“Timepoint”problem(Reuptakeinhibitors)Potentialdisadvantages“Off-ta22IntroductionUpsanddownsofendocannabinoidsindiseaseTherapeuticuseofindirectagonistsTherapeuticuseofinverseagonists/antagonistsIntroduction23CB1receptorantagonistsCatabolismdisordersNicotineorCocainedependenceOthersCB2receptorantagonistsAnti-inflammatoryAnti-allergicAutoimmunedisordersCB1receptorantagonists24CB1receptorantagonists/inverseagonistsinclinicaltrials(notall)CB1receptorantagonists/inver25CB2receptorantagonists/inverseagonistsinpreclinicaltrials(notall)CB2receptorantagonists/inver26PotentialdisadvantagesNotasneutralantagonistsbutasinverseagonists(non-specificeffects)InterferencewithunconcerneddisordersinwhichendocannabinoidsmighthaveprotectiveeffectsPotentialdisadvantagesNotas27Perhapsnoothersignallingsystemdiscoveredduringthepast15yearsisraisingasmanyexpectationsforthedevelopmentofnewtherapeuticdrugs,encompassingsuchavarietyofpathologicalconditions,targetingsomanydifferentorgansandtissues,andusingsuchawiderangeofpotentialstrategiesfortreatment,astheendocannabinoidsystem.Perhapsnoothersignallingsy28Targetingtheendocannabinoidsystem:

toenhanceorreduce?VincenzoDMNATUREREVIEWS|DRUGDISCOVERY,2008Targetingtheendocannabinoid29IntroductionUpsanddownsofendocannabinoidsindiseaseTherapeuticuseofindirectagonistsTherapeuticuseofinverseagonists/antagonistsIntroduction30CannabinoidEndocannabinoidAnandamide2-AGCannabinoid31EndocannabinoidSystem內(nèi)源性大麻素系統(tǒng)課件32RecptorsCannabinoidreceptorsCB1andCB2Anandamidehashighestaffinity2-AGhashighestefficacyRetrogradesignallingOther“receptors”ofcannabinoidTRPV1GPR55???PPARs-alpha/beta???RecptorsCannabinoidreceptors33EndocannabinoidSystem內(nèi)源性大麻素系統(tǒng)課件34DevelopmentstrategyofendocannabinoidsystemtargeteddrugDirectagonist×TetrahydrocannabinolanditssyntheticanaloguesNewerdrugs√InhibiterofendocannabinoiddegradationSA-47URB597Cannabinoidreceptor(CB)antagonistsRimonabantTaranabantDevelopmentstrategyofendoca35IntroductionUpsanddownsofendocannabinoidsindiseaseTherapeuticuseofindirectagonistsTherapeuticuseofinverseagonists/antagonistsIntroduction36NOTEMeasurementAmountsofendocannabinoid×Changesofendocannabinoidlevel√BidirectionalorparadoxeffectsPositiveandnegativeProtectiveandworseningMultiplefunctionaloutcomeNOTEMeasurement37EattingdisordersPhysiologicalconditionAdaptiveresponseIntakeoffoodCopewiththelackoffoodPathologicalconditionDisruptedorexigenicmechanismEattingdisordersPhysiological38Neural-diseaseNeurodegenerationParlinson’sdiseaseBeta-amyloid-cytotoxicity(AD)MultiplesclerosisandexperimentalallergicencephalitisAmyotrophiclateralsclerosisAnxietyanddepressionPainandinflammationNeural-diseaseNeurodegeneratio39EndocannabinoidSystem內(nèi)源性大麻素系統(tǒng)課件40Rolesofendocannabinoidsduring

centralneuroinflammationRolesofendocannabinoidsduri41Rolesofendocannabinoidsduring

peripheralneuroinflammationRolesofendocannabinoidsduri42LiverdiseaseandosteoporosisDetrimentalandbeneficialeffectsofCB1andCB2respectivelyHepaticpathologyChronicupregulationofendocannabinoidlevelOsteoporosisLiverdiseaseandosteoporosis43OtherdiseasesCancerGastrointestinalinflammationOtherdiseases44IntroductionUpsanddownsofendocannabinoidsindiseaseTherapeuticuseofindirectagonistsTherapeuticuseofinverseagonists/antagonistsIntroduction45InhibitorsofcatabolismInhibitorsofcatabolismFAAHblockers–moreselectivetowardsanandamideMAGLsblockers–specificfor2-AGURB-597(preclinicalstage)AA-5-HT(alsoantagonizeTRPV1)SA-72InhibitorsofcatabolismInhibi46Endocannabinoidindirectagonists:inhibitorsofFAAHandMAGLEndocannabinoidindirectagoni47InhibitorsofcellularreuptakeInhibitorsAromaticacylamidederivativesAM404VDM-11OMDM-1andOMDM-2etc.Carbamoyl-tetrazolesLY2183240(alsoaFAAHinhibitor)PotentialindicationstestedinanimalmodelsInhibitorsofcellularreuptak48Endocannabinoidindirectagonists:InhibitorsofcellularreuptakeEndocannabinoidindirectagoni49Potentialdisadvantages“Off-targets”problem(FAAHinhibitors)Raisenon-endocannabinoidsubstratesActivatenon-cannabinoidreceptors(e.g.TRPV1)AA-5-HT:FAAH/TRPV1blocker(strategy)Somereuptakeinhibitor(AM404)“Nodevelop”(MAGLsinhibitors)“Timepoint”problem(Reuptakeinhibitors)Potentialdisadvantages“Off-ta50IntroductionUpsanddownsofendocannabinoidsindiseaseTherapeuticuseofindirectagonistsTherapeuticuseofinverseagonists/antagonistsIntroduction51CB1receptorantagonistsCatabolismdisordersNicotineorCocainedependenceOthersCB2receptor

溫馨提示

  • 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間，僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論